Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) passed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $4.43 and traded as high as $4.63. Galmed Pharmaceuticals shares last traded at $4.59, with a volume of 302,067 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Galmed Pharmaceuticals Price Performance

The firm has a market cap of $4.78 million, a P/E ratio of -0.30 and a beta of 0.67. The company’s 50-day moving average is $4.43 and its two-hundred day moving average is $4.68.

Galmed Pharmaceuticals (NASDAQ:GLMD) last announced its quarterly earnings data on Wednesday, September 2nd. The biopharmaceutical company reported ($2.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.12) by $0.26.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd. is an Israeli clinical-stage biopharmaceutical company focused on developing treatments for liver and metabolic diseases. The company’s research has centered on nonalcoholic steatohepatitis (NASH), now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease associated with fat accumulation and inflammation.

Galmed’s lead product candidate has been aramchol, an orally administered synthetic conjugate of a fatty acid and bile acid.